Selective IMRT for Locally Advanced Head and Neck Carcinoma With Concurrent Panitumumab
Status:
Withdrawn
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
This is a non-randomized phase II study of targeted radiotherapy (RT) administered
concurrently with panitumumab in patients with locally advanced squamous carcinoma of the
head and neck.